Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting
About Rubius Therapeutics, Inc.
- NASDAQ: $RUBY
- Notified: $6.00
- 08:01 EDT
